Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058026920> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2058026920 endingPage "64" @default.
- W2058026920 startingPage "59" @default.
- W2058026920 abstract "The aim of this study was to determine the efficacy and tolerability of a biochemotherapy regimen, including low-dose subcutaneous interleukin-2 and temozolomide, in patients with metastatic melanoma. Treatment consisted of temozolomide (150 mg/m2 per day on days 1–5), cisplatin (20 mg/m2 per day intravenously on days 1–4), vinblastine (1.5 mg/m2 per day on days 1–4), interleukin-2 (4.5 MU/m2 per day subcutaneously on days 5–8) and interferon-α2b (5 MU subcutaneously on days 5–9, 11, 13, 15, every 28 days). Thirty-six patients were included. Patients with poor prognostic factors were not excluded. Seventeen patients (47%) had been treated previously in an adjuvant setting with interferon-α. Four patients (11%) had been treated previously with chemotherapy and six (17%) had been treated with other biochemotherapy regimens. The distribution by American Joint Committee on Cancer staging was as follows: M1a in two patients (6%), M1b in 11 patients (31%) and M1c in 23 patients (64%). At inclusion, seven patients (19.4%) had cerebral metastases that had previously been treated with whole brain radiotherapy. For thirty-four evaluable patients, seven (20.5%) achieved an objective response. Overall, metastatic disease was substantially decreased or temporarily stabilized in 11 patients (32.4%; 95% confidence interval, 17.4–50.5). Responses were observed for all locations. The central nervous system was the initial site of relapse in two responding patients. The median survival was 10 months. The main toxicities noted were haematological (grades 3–4): neutropenia (1.8%), thrombocytopenia (1.8%) and anaemia (1.2%). It can be concluded that this regimen is well tolerated and has a modest activity despite the poor prognosis of our patient population. The low haematological toxicity rate obtained suggests that higher doses could be tried." @default.
- W2058026920 created "2016-06-24" @default.
- W2058026920 creator A5001259660 @default.
- W2058026920 creator A5008890557 @default.
- W2058026920 creator A5010040304 @default.
- W2058026920 creator A5036932434 @default.
- W2058026920 creator A5039705933 @default.
- W2058026920 creator A5056168484 @default.
- W2058026920 creator A5057220121 @default.
- W2058026920 creator A5059946449 @default.
- W2058026920 creator A5060937087 @default.
- W2058026920 creator A5079760997 @default.
- W2058026920 creator A5080007233 @default.
- W2058026920 creator A5080644769 @default.
- W2058026920 date "2006-02-01" @default.
- W2058026920 modified "2023-10-16" @default.
- W2058026920 title "Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-α in patients with metastatic melanoma" @default.
- W2058026920 cites W1831317193 @default.
- W2058026920 cites W1845919752 @default.
- W2058026920 cites W1917632054 @default.
- W2058026920 cites W1950572133 @default.
- W2058026920 cites W1972458901 @default.
- W2058026920 cites W2004138031 @default.
- W2058026920 cites W2018046489 @default.
- W2058026920 cites W2082308931 @default.
- W2058026920 cites W2083442620 @default.
- W2058026920 cites W2127123639 @default.
- W2058026920 cites W2136271044 @default.
- W2058026920 cites W2282985545 @default.
- W2058026920 doi "https://doi.org/10.1097/01.cmr.0000195697.58013.b7" @default.
- W2058026920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16432457" @default.
- W2058026920 hasPublicationYear "2006" @default.
- W2058026920 type Work @default.
- W2058026920 sameAs 2058026920 @default.
- W2058026920 citedByCount "19" @default.
- W2058026920 countsByYear W20580269202015 @default.
- W2058026920 countsByYear W20580269202021 @default.
- W2058026920 countsByYear W20580269202022 @default.
- W2058026920 crossrefType "journal-article" @default.
- W2058026920 hasAuthorship W2058026920A5001259660 @default.
- W2058026920 hasAuthorship W2058026920A5008890557 @default.
- W2058026920 hasAuthorship W2058026920A5010040304 @default.
- W2058026920 hasAuthorship W2058026920A5036932434 @default.
- W2058026920 hasAuthorship W2058026920A5039705933 @default.
- W2058026920 hasAuthorship W2058026920A5056168484 @default.
- W2058026920 hasAuthorship W2058026920A5057220121 @default.
- W2058026920 hasAuthorship W2058026920A5059946449 @default.
- W2058026920 hasAuthorship W2058026920A5060937087 @default.
- W2058026920 hasAuthorship W2058026920A5079760997 @default.
- W2058026920 hasAuthorship W2058026920A5080007233 @default.
- W2058026920 hasAuthorship W2058026920A5080644769 @default.
- W2058026920 hasConcept C126322002 @default.
- W2058026920 hasConcept C141071460 @default.
- W2058026920 hasConcept C197934379 @default.
- W2058026920 hasConcept C2776694085 @default.
- W2058026920 hasConcept C2776907518 @default.
- W2058026920 hasConcept C2777063308 @default.
- W2058026920 hasConcept C2777132456 @default.
- W2058026920 hasConcept C2777389519 @default.
- W2058026920 hasConcept C2778375690 @default.
- W2058026920 hasConcept C2780964509 @default.
- W2058026920 hasConcept C2781413609 @default.
- W2058026920 hasConcept C71924100 @default.
- W2058026920 hasConcept C90924648 @default.
- W2058026920 hasConceptScore W2058026920C126322002 @default.
- W2058026920 hasConceptScore W2058026920C141071460 @default.
- W2058026920 hasConceptScore W2058026920C197934379 @default.
- W2058026920 hasConceptScore W2058026920C2776694085 @default.
- W2058026920 hasConceptScore W2058026920C2776907518 @default.
- W2058026920 hasConceptScore W2058026920C2777063308 @default.
- W2058026920 hasConceptScore W2058026920C2777132456 @default.
- W2058026920 hasConceptScore W2058026920C2777389519 @default.
- W2058026920 hasConceptScore W2058026920C2778375690 @default.
- W2058026920 hasConceptScore W2058026920C2780964509 @default.
- W2058026920 hasConceptScore W2058026920C2781413609 @default.
- W2058026920 hasConceptScore W2058026920C71924100 @default.
- W2058026920 hasConceptScore W2058026920C90924648 @default.
- W2058026920 hasIssue "1" @default.
- W2058026920 hasLocation W20580269201 @default.
- W2058026920 hasLocation W20580269202 @default.
- W2058026920 hasOpenAccess W2058026920 @default.
- W2058026920 hasPrimaryLocation W20580269201 @default.
- W2058026920 hasRelatedWork W2000912248 @default.
- W2058026920 hasRelatedWork W2058026920 @default.
- W2058026920 hasRelatedWork W2059172527 @default.
- W2058026920 hasRelatedWork W2119233294 @default.
- W2058026920 hasRelatedWork W2125837906 @default.
- W2058026920 hasRelatedWork W2163845360 @default.
- W2058026920 hasRelatedWork W2343957142 @default.
- W2058026920 hasRelatedWork W2356441863 @default.
- W2058026920 hasRelatedWork W2412065260 @default.
- W2058026920 hasRelatedWork W40246373 @default.
- W2058026920 hasVolume "16" @default.
- W2058026920 isParatext "false" @default.
- W2058026920 isRetracted "false" @default.
- W2058026920 magId "2058026920" @default.
- W2058026920 workType "article" @default.